Activist investor famous for his high-profile battle with Herbalife claims short was 'most philanthropic investment I have ever made.'» Read More
Fresh of a big win from investing in human drugs, Bill Ackman is now focused on pharmaceuticals for animals.
Before you get too excited about Friday's move, "Mad Money" host Jim Cramer puts it in context.
Heads he wins. Tails he wins. That was the situation Bill Ackman found himself in — or perhaps more accurately, orchestrated — on Monday.
Deals worth $100 billion on Monday put the Street on pace for a year rivaling the dot-com bubble era and the private equity surge just before the financial crisis.
Jim Cramer reviews the acquisition of Allergan by Actavis to judge just how lucrative the deal could really be for shareholders.
Bill Ackman isn't the only hedge fund manager who likely made big money on the Allergan deal.
The deal beats the unsolicited bid last spring of above $50 billion from Valeant, which teamed with Bill Ackman.
An unconfirmed rumor appears to be having a major impact on Wal-Mart options trading.
Bill Ackman partnered with another hedge fund to buy a 10 percent stake in animal health company Zoetis, Dow Jones reported.
Herbalife CEO John DeSimone spoke to CNBC's "Halftime Report" in an exclusive interview.
Lower guidance shows Herbalife faces challenges outside the relentless attacks from activist investors, says CNBC's Jim Cramer.
Herbalife reported earnings that missed expectations and offered a sales outlook that was well below forecasts, sending shares plunging 13 percent.
The building has ruled over New York real estate, but now its sales may be coming back down to Earth.
Discovery Capital has been battered by volatility, according to a report that disclosed losses of more than 20 percent in one of its main funds.
Herbalife CEO, Michael Johnson, talks about the FTC investigation and Bill Ackman accusations in a recent interview with Los Angeles Magazine.
Wall Street is spending more on the midterms than ever before—particularly in support of the GOP—but it's not from whom you might think.
Jim Cramer takes on activist calls to CEOs strong performing companies, and suggests they realign their attention
U.S. stocks ended about 2 percent higher on Wednesday as markets extended gains on the FOMC minutes and recovered from Tuesday's selloff.
Founder and CEO, Pershing Square Capital Management
The SEC accuses two men of insider trading ahead of Bill Ackman's announcement that his Pershing Square fund had taken a short position on Herbalife.